Oncolytic viral therapies - the clinical experience (Q36318202)

13 August 2017

1 reference

title

Oncolytic viral therapies - the clinical experience (English)

1 reference

13 August 2017

1 reference

2

Robert L Martuza

1 reference

13 August 2017

Manish Aghi

1

1 reference

PubMed ID

16299539

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

52

1 reference

13 August 2017

7802-7816

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209037

13 August 2017

0 references

cites work

Prodrug activation enzymes in cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Public health. Treating vaccine reactions: two lifelines, but no guarantees

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Inhibition of reovirus by mycophenolic acid is associated with the M1 genome segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Present status of oncolytic virus studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209037

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209037

1 reference

13 August 2017

1 reference

PubMed ID

16299539